Halozyme Director Amends Annual RSU Grant Count

Executive Summary

On October 8, 2026, Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Form 4/A amendment on behalf of Director Bernadette Connaughton. The amendment corrects the reported annual restricted stock unit (RSU) award granted on May 5, 2026, decreasing the recorded grant from 6,796 RSUs to 3,796 RSUs.

Transaction Details

• Reporting Insider: Bernadette Connaughton (Director)
• Security: Common Stock (Restricted Stock Units)
• Transaction Code: A (Award / Grant)
• Transaction Date: May 5, 2026
• Shares Acquired: 3,796 (revised from 6,796)
• Price per Share: $0.00
• Post-Transaction Beneficial Ownership: 42,294 direct shares

Filing Background & Significance

• Purpose of Amendment: Solely filed to rectify an overstatement in the initial May 7, 2026 Form 4, which inadvertently listed 6,796 RSUs instead of the correct 3,796 RSUs granted under the Issuer's standard director compensation program.
• Vesting Terms: The RSUs vest in full on the earlier of May 5, 2027 or the date of Halozyme's next annual meeting of stockholders.
• Market Implications: Low significance. This is a non-discretionary administrative correction to routine board equity compensation and involves no open-market buying or selling.